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Abstract
Hepadnaviruses, including hepatitis B virus (HBV), a highly relevant human pathogen, are small enveloped DNA viruses that
replicate via reverse transcription. All hepadnaviruses display a narrow tissue and host tropism. For HBV, this restricts
efficient experimental in vivo infection to chimpanzees. While the cellular factors mediating infection are largely unknown,
the large viral envelope protein (L) plays a pivotal role for infectivity. Furthermore, certain segments of the PreS domain of L
from duck HBV (DHBV) enhanced infectivity for cultured duck hepatocytes of pseudotyped heron HBV (HHBV), a virus
unable to infect ducks in vivo. This implied a crucial role for the PreS sequence from amino acid 22 to 90 in the duck tropism
of DHBV. Reasoning that reciprocal replacements would reduce infectivity for ducks, we generated spreading-competent
chimeric DHBVs with L proteins in which segments 22–90 (Du-He4) or its subsegments 22–37 and 37–90 (Du-He2, Du-He3)
are derived from HHBV. Infectivity for duck hepatocytes of Du-He4 and Du-He3, though not Du-He2, was indeed clearly
reduced compared to wild-type DHBV. Surprisingly, however, in ducks even Du-He4 caused high-titered, persistent,
horizontally and vertically transmissable infections, with kinetics of viral spread similar to those of DHBV when inoculated at
doses of 10
8 viral genome equivalents (vge) per animal. Low-dose infections down to 300 vge per duck did not reveal a
significant reduction in specific infectivity of the chimera. Hence, sequence alterations in PreS that limited infectivity in vitro
did not do so in vivo. These data reveal a much more complex correlation between PreS sequence and host specificity than
might have been anticipated; more generally, they question the value of cultured hepatocytes for reliably predicting in vivo
infectivity of avian and, by inference, mammalian hepadnaviruses, with potential implications for the risk assessment of
vaccine and drug resistant HBV variants.
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Introduction
Hepadnaviruses including hepatitis B virus (HBV), the causative
agent of B-type hepatitis in humans, are small enveloped
hepatotropic DNA viruses that replicate by reverse transcription
([1]; for reviews see [2,3]). Related viruses have been found in
some mammals (orthohepadnaviruses), e.g. woodchucks (WHV),
and in selected bird species (avihepadnaviruses), e.g. ducks
(DHBV) and herons (HHBV). In general, each of these viruses
can infect only a limited range of hosts [4,5].
Nonetheless, all hepadnaviruses share a similar genome
organization and replication strategy. Upon infection the about
3 kb relaxed circular (RC) DNA genome in virions is converted
into covalently closed circular (ccc) DNA that acts as transcription
template. The greater-than-genome length pregenomic (pg) RNA
serves as mRNA for the capsid protein and the reverse
transcriptase (P protein), and via specific P-RNA interactions is
encapsidated and reverse transcribed into progeny RC-DNA (for
review, see [6]). New nucleocapsids can either recycle the RC-
DNA to the nucleus for cccDNA amplification, or be secreted after
envelopment by the surface, or envelope, proteins (for review, see
[7]) that are translated from subgenomic RNAs. N terminal
addition to the small surface protein (S), a transmembrane protein,
of the PreS1 plus PreS2 domains in orthohepadnaviruses, or of a
single about 160 amino acid (aa) PreS domain in avihepadna-
viruses, creates the respective large envelope proteins (L). PreS2
plus S form the middle (M) protein in the mammalian viruses.
Notably, the preS/S open reading frames (ORFs) overlap entirely
with the P ORF (Figure 1A).
Hepatotropism is largely attributable to the requirement for
hepatocyte-enriched transcription factors [8]; host range appears
to be mainly controlled at the early steps of virus attachment and
entry as inferred from the ability of several non-infectable cell
lines, even of heterologous species origin [9], to produce infectious
virions when transfected with cloned hepadnaviral DNA.
Infection, however, usually requires primary hepatocytes. Because
none of the natural hosts is an established experimental animal,
few different species have been investigated; these include
hepatocytes from humans and tupaias [10,11], or woodchucks
(reviewed in [12]); Pekin ducks (Anas platyrhynchos var. domestica)
provide the only feasible source for hepatocytes of a genuine
avihepadnavirus host (reviewed in [13]). Even greater restrictions
apply to in vivo experiments. Collectively the few published studies
suggest the existence of a species barrier that prevents efficient
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transmitted to chimpanzees [14] but not [15], or only extremely
inefficiently [16], to baboons; WHV was not infectious for ground
squirrels [17]; and DHBV does not infect chicken [18]. Notably,
though, this barrier is not absolute; for instance, Beechey Ground
Squirrel HBV (GSHV) was infectious for woodchucks and
chipmunks [19], though not mice or rats [20]. In vitro, host
tropism appears more relaxed as shown by the relatively efficient
infectibility of tupaia hepatocytes [10,11] by HBV and woolly
monkey HBV (WMHBV; [21]), or of duck hepatocytes by crane
hepatitis B virus [22]. While these examples attest to an as yet
poorly understood complexity of hepadnaviral host tropism
(reviewed in [5]), the inability of HHBV to establish detectable
infection in ducks is solidly established [23,24].
Though numerous cellular HBV binding proteins have been
reported (reviewed in [4]), the receptors for orthohepadnaviruses
are not known; the major candidate receptor for DHBV,
carboxypeptidase D (CPD; formerly gp180 [25]), is ubiquitously
expressed and highly conserved between bird species; hence it can
explain neither tissue nor host tropism. Glycine decarboxylase was
proposed as a co-receptor [26] yet whether its coexpression with
CPD renders non-infectable cells susceptible to DHBV infection
was not reported. On the virus side, by contrast, a pivotal role of
the PreS domains of the L proteins for infection is firmly
established (Figure 1B). Anti-PreS antibodies can block HBV [27]
and DHBV infection [28–31], and many mutations within aa 1 to
75 of HBV PreS1 [32] and aa 2 to 115 [33] of DHBV PreS (D-
PreS) abrogate infectivity, as does prevention of PreS myristoyla-
tion. In addition, short C proximal PreS regions are essential for
nucleocapsid envelopment and hence for infectious virion
formation (reviewed in [4,7]).
The PreS regions display the highest sequence divergence
among hepadnaviruses (42% aa identity for DHBV versus HHBV
PreS [He-PreS], compared to 84% for the respective S proteins),
suggesting that PreS also harbors elements governing host range.
In a landmark study, Ishikawa and Ganem [23] laid the
foundation for the current model of host-range determinants in
hepadnaviruses, using primary duck hepatocytes (PDH) and
DHBV as homologous, and HHBV as a heterologous virus.
HHBV was capable of establishing a low level infection in PDH
(100 to 1,000-fold less efficiently than DHBV). Infectivity of an
envelope-deficient (env
2) HHBV genome increased upon pseu-
dotyping with chimeric HHBV envelope proteins containing the
entire D-PreS domain or its segments 1–90 and 22–108, but not
43–161. It was concluded that the common segment 22–90, or
possibly its subsegment 22–37 (T. Ishikawa, personal communi-
cation), governs the species-specificity of avihepadnaviral infection.
In apparent accord, D-PreS peptides comprising aa 2–41 can
efficiently block PDH infection by DHBV [34]. Although a
Figure 1. Hepadnavirus genome organization and functional PreS domains. (A) DHBV genome. The black line represents the vector-borne
1.16 genome driven by a heterologous promoter; the grey arrow symbolizes the viral core promoter controlling pgRNA expression on cccDNA.
Numbers are nucleotide positions. Indicated cis-elements: DR, direct repeat; e and eII, RNA encapsidation signals; E and M, required for RC-DNA
formation. Bars represent the indicated ORFs; TP, Terminal Protein domain of P. (B) Functional regions in DHBV PreS. Numbers are amino acid
positions; myr, myristic acid. The carboxypeptidase D (CPD) binding region [50] contains an essential (solid line) and an auxiliary part (dashed
extension). The long and short forms of the proposed host-determining region (HDR) are denoted by white bars. (C) Chimeric PreS regions used.
Segments from D-PreS and He-PreS present in the chimeric viruses are indicated. (D) DHBV versus HHBV PreS. The PreS amino acid sequences of
DHBV16 [70] and HHBV4 [24] are shown as aligned by the Clustal6algorithm. The proposed HDR forms are boxed. Numbers are amino acid positions
for D-PreS. Dots, identical amino acids; dashes, gaps.
doi:10.1371/journal.ppat.1000230.g001
Author Summary
Hepatitis B virus (HBV) associated liver disease is a leading
cause of death worldwide. Host range restrictions limit
experimental HBV infections largely to chimpanzees or
isolated human hepatocytes. A narrow host range is
shared by the animal hepadnaviruses, e.g. from ducks
(DHBV) and herons (HHBV); HHBV does not infect ducks
though it can establish a low-level infection in cultured
duck hepatocytes. Host tropism is thought to be mediated
by the PreS domain of the large viral envelope protein,
because certain duck virus PreS segments introduced into
the envelope of spreading-incompetent HHBV pseudo-
types enhanced infectivity for duck hepatocytes. Expecting
that reciprocal exchanges in DHBV would negatively
impact duck tropism, we generated chimeric DHBVs in
which the PreS regions in question are derived from HHBV
and which are autonomously spreading-competent; this
allowed us to directly compare their infectivity for duck
hepatocytes and ducks. Surprisingly, even the chimera
with the largest portion of HHBV sequence was as
infectious for ducks as authentic DHBV; in vitro infectivity,
however, was substantially reduced. These unexpected
differences question the value of cultured hepatocytes to
reliably predict in vivo infectivity of avihepadnaviruses and,
by inference, also that of vaccine escape and therapy
resistant HBV variants.
Avihepadnavirus Host Range Determinants Revisited
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(here termed short form), or possibly 22 to 90 (long form;
Figure 1B,D), are often referred to as the host-determining region
(HDR) of avihepadnaviruses [4,34,35]. Similar pseudotype data
with L protein chimeras between HBV and WMHBV on human
hepatocytes [36] suggested that essentially the same holds for the
orthohepadnaviruses, although recent in vitro infection studies
[37,38] using hepatitis delta virus (HDV), an RNA virus that
depends on the envelope of HBV to form infectious particles [39],
are difficult to reconcile with such a simple model (see Discussion).
Most importantly, the role of the supposed HDRs in a true in
vivo hepadnavirus infection, requiring autonomously replicating
viruses that inheritably encode the chimeric envelope proteins, has
never been assessed.
The aim of this study was to provide such information. We could,
indeed, confirm an increased PDH infectivity of HHBV pseudo-
types carrying selected D-PreS segments, including aa 22–37.
However, reciprocal replacement of this sequence in an autono-
mous chimeric DHB virus had no negative impact on infectivity for
duck hepatocytes or ducks. Most surprisingly, a DHBV chimera in
which the entire proposed HDR was replaced by the corresponding
heron virus sequence (Du-He4), was poorly infectious for duck
hepatocytes yet was nearly as, if not equally infectious for ducks as
wild-type DHBV. Thus although the heterologous PreS sequence
limited in vitro infectivity it did not do so in vivo. These results
question the value of isolated hepatocytes to reliably predict in vivo
host range of avian, and by inference, mammalian hepadnaviruses,
with consequences for the risk assessment of human HBV variants
that seem to inevitably emerge during current nucleos(t)ide analog
based therapeutic regimens of chronic hepatitis B; notably, due to
the overlapping ORF arrangement, such mutations in P also affect
the envelope genes.
Results
Experimental design
Pseudotypes can not spread in vivo. We therefore aimed at
introducing the supposedly relevant PreS segment exchanges into
autonomous chimeric viruses. If a specific PreS segment
determined the duck tropism of DHBV, its replacement by heron
virus sequence should decrease infectivity for ducks; the segments
replaced in the respective DHBV chimeras were D-PreS 22–37
(Du-He2), 22–90 (Du-He4), and 38–90 (Du-He3), and in an
additional chimera not considered here in detail, 91–161 (Du-
He7). Concerns for the in vivo experiments were the prevalence of
congenital DHBV infections in domestic ducks (10–20% of the
ducks used here), and the high in vivo infectivity of DHBV [40]
such that even minute contaminations of the inocula might result
in wild-type virus infection. For easy distinction, all recombinant
viruses, including the DHBV16 (Genbank accession: K01834)
derivative DHBVm1 serving as reference wild-type virus, were
therefore genetically tagged by unique restriction sites (Figure
S1A). PreS segment swapping generates mutant P proteins and
could affect genomic cis-elements [6,41]. However, replication
competence and envelopment were not negatively affected in the
three chimeras (and neither in Du-He7). In transfected LMH cells,
all produced similar, if not higher (DuHe3, Du-He4), amounts of
intracellular RC- and double-stranded linear (dsL) progeny DNA
(Figure 2A), and of secreted, bona fide enveloped particles. This was
demonstrated by the strongly (at least 20-fold) increased labeling of
the particle-borne virus genome in the presence versus absence of
detergent during endogenous polymerase reactions (Figure 2B).
These reactions rely on the ability of the genome-linked
(endogenous) P protein to incorporate exogeneously added dNTPs
into the incomplete genome yet only if dNTP access to the
nucleocapsid lumen is not blocked by an intact envelope.
Heterologous replacement of the long, though not the
short, form of the supposed HDR reduces infectivity of
DHBV for cultured duck hepatocytes
Titers of transfection-derived virions were quantified as viral
genome equivalents (vge); multiplicities of infection (MOI) were
operationally defined as vge per inoculated cell. PDH were
inoculated at MOI 100 with the recombinant chimeras, and
recombinant DHBVm1 and HHBV as controls. Infectivity and
the kinetics of infection (Figure 3) were scored by Southern
blotting and by quantitative PCR (qPCR) [42] of intracellular viral
DNAs, and of secreted vge between day 1 and day 15 post
inoculation (p.i.); genotypes were confirmed by restriction analysis
(Figure S1B).
Du-He2 behaved in all aspects indistinguishably from the
reference virus DHBVm1. Already at day 3 p.i. both gave strong
cccDNA and ssDNA signals; while the RC DNA signals could
originate, in part, from the inocula they were clearly enhanced
compared the other three samples. Signal intensities increased
about 10-fold to day 7, and further to day 15. Both Du-He3 and
Du-He4 produced 10- to 30-fold weaker signals until day 7 p.i.;
thereafter the difference decreased to 4- to 6-fold, probably
because DHBVm1 and Du-He2 had already reached a plateau. A
Figure 2. Chimeric viruses are replication-competent and form
enveloped virions. (A) Southern blot for intracellular viral DNAs. LMH
cells were transfected with expression vectors for the indicated virus
genomes, and viral DNAs were detected using a composite DNA probe
that recognizes DHBV and HHBV with similar efficiency (see Protocol
S1). RC, relaxed circular DNA; dsL, double-stranded linear DNA; M1, dsL
DHBV DNA fragments of the indicated sizes (in kb); M2, covalently
closed circular (ccc) 3 kb plasmid containing DHBV sequence. (B)
Detergent dependence of endogenous polymerase activity. Culture
supernatants from the transfected LMH cells were subjected to
immunoprecipitation with a monoclonal antibody against D-PreS which
also recognizes the chimeric D-PreS proteins but not He-PreS. Serum-
derived DHBV served as control. Equal aliquots of the immune pellets
were subjected to endogenous polymerase assay conditions in the
absence, or in the presence of NP-40 detergent which increased signal
intensities, in all samples, by at least 20-fold. Numbers below each lane
indicate the concentration of viral genome equivalents (vge) per mL of
culture supernatant as determined by qPCR (see Protocol S1); standard
deviations are based on four (DHBVm1) or six (all others) independent
determinations; residual plasmid DNA accounted for at most one
percent of the signals.
doi:10.1371/journal.ppat.1000230.g002
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for Du-He7 which had also not displayed any obvious defects in
replication or envelopment in transfected LMH cells (data not
shown). Signals for wt-HHBV remained two to three orders of
magnitude below those from DHBVm1; however, infection was
detectable by formation of small amounts of cccDNA and an
about 10-fold net increase in intracellular and secreted viral DNAs
from day 7 to day 15 p.i.. Thus, as expected if D-PreS 22–90 was
important for the host tropism of DHBV, its exchange, or that of
D-PreS 38–90 (Du-He3) or 91–161 (Du-He7), by He-PreS
sequence markedly reduced infectivity for PDH whereas D-PreS
22–37 could be replaced without any negative impact; from this
one would conclude that D-PreS 22–37 does not contribute to host
discrimination. This was surprising given the reported stimulatory
effect of D-PreS 22–37 on HHBV pseudotype infectivity for PDH
and prompted us to repeat and extend the original pseudotyping
experiments [23].
Specific D-PreS segments including aa 22–37 can
enhance PDH infectivity of HHBV pseudotypes
Pseudotypes were generated by complementation of env
2
HHBV and DHBV genomes with the envelope proteins of wild-
type DHBV and HHBV, and with chimeric HHBV PreS/S
proteins carrying D-Pres 1–90 and 22–108 [23], 22–37 and 22–90,
or the PreS domain from crane HBV (CHBV1; Genbank
accession: AJ441111) which is reportedly infectious for PDH
[22]. Pseudotype yields were all similar, as determined by
quantitation of envelope-protected viral DNAs. Autologously
pseudotyped DHBV was applied at MOI 1000, 100 and 10 to
calibrate PDH infection efficiency, all others were used at MOI
1000. Supernatant from cells transfected with the env
2 DHBV
genome plus a vector encoding only DHBV S (PreS
2) served as
background control. Cells were harvested at day 7 p.i. and
analyzed for intracellular virus DNA by Southern blotting
(Figure 4).
Though the RC-DNA signals were less informative (see above),
the levels of the other viral DNA forms, including cccDNA,
differed drastically, confirming in part the previously reported
results. Autologously pseudotyped env
2 DHBV gave still a clear
cccDNA signal at MOI 10, slightly exceeding that obtained with
HHBV PreS/S at MOI 1000; hence, as reported [23] the heron
virus envelope conferred an about 100- to 1,000-fold reduced
PDH infectivity. Infectivity of HHBV env
2 was rescued most
effectively by a complete DHBV envelope (D-PreS/S) yet, even in
combination with HHBV S, the entire D-PreS domain and its
segments 22–37, 22–108, as well as CHBV-PreS led to significant
Figure 3. In vitro infectivity of chimeric viruses. PDH were incubated with the recombinant viruses at MOI 100. Cells were harvested at the
indicated days post inoculation (p.i.). (A) Southern blot for intracellular viral DNAs. Abbreviations of the different DNA forms are as in the legend to
Figure 2A. For day 15 p.i., only the lanes with Du-He4 and HHBV are shown. (B) Quantitation of intracellular viral DNAs by qPCR. Viral DNA amounts
were normalized to cell numbers by qPCR as detailed in Protocol S1; for the early time points of the poorly infectious samples the values are
maximum estimates due to the presence of some RC DNA from the inocula. (C) Quantitation of progeny virus production by qPCR. Viral titers are
given as vge per ml culture fluid from approximately 10
6 cells per day. Standard deviations (bars) are based on at least two, and usually four to five
independent determinations.
doi:10.1371/journal.ppat.1000230.g003
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These data were corroborated by qPCR of the intracellular
replicative intermediates (RIs) although the accuracy of the low
values was probably limited by contributions from inoculum
derived RC-DNA. We cannot offer a trivial explanation for the
discordant data regarding D-PreS 1–90; the sequence of the
expression vector was correct, and enveloped particle formation
was as efficient as with the other constructs. Most importantly,
however, these data confirmed that D-PreS 22–108, and in
particular D-PreS 22–37, increased infectivity of the HHBV
envelope for PDH nearly as efficiently as the entire D-PreS
domain. Thus in this test system introducing the D-PreS 22–37
segment into the HHBV envelope did affect host-specific
infectivity whereas its reciprocal removal from the DHBV
envelope in Du-He2 did not.
Two chimeras with heterologous PreS sequences that
cause poor PDH infectivity are highly infectious in vivo
To test in vivo infectivity of the chimeric viruses, three 3 day old
ducklings each were inoculated with 10
8 vge of recombinant
chimeras Du-He2, Du-He3, and Du-He4; 7.5610
7 vge are
estimated to be sufficient to deliver virus to about 10% of liver
cells in 1-day-old ducklings [40]. Controls included recombinant
wt-HHBV, DHBV16 and DHBVm1, and serum DHBV3
(Genbank accession: DQ195079) from a congenitally infected
duck (10
9 vge). Between one and three animals from each group,
except those inoculated with HHBV, showed detectable surface
protein antigenemia at day 7 p.i., and remained viremic until the
end of the experiment at week 15; intrahepatic virus DNA levels at
this time-point were comparable, regardless of the specific PreS
sequence (data not shown). Genotypes were confirmed by
restriction analysis, excluding wild-type virus as a source of
infection in the animals inoculated with the chimeras (Figure S2A).
None of the animals showed any overt pathogenicity (no major
weight reduction or retarded growth [43], no gross abnormalities
of the inner organs). Two persistently Du-He4 infected females
were kept for more than one year, without significant decline in
viremia. Hence even the poorly PDH infectious chimeras Du-He3
and Du-He4 were able to establish persistent infections in ducks;
notably though, no signs of infection were detectable in 6 animals
inoculated under identical conditions with Du-He7 (not shown).
Efficient horizontal and vertical transmission of Du-He4
virus in ducks
To test whether Du-He4 could horizontally and vertically be
transmitted, three ducklings (#4/17 to #4/19) were inoculated
with Du-He4 positive serum from one of the above described
animals (10
8 vge per animal); serum containing DHBVm1 served
as control (animals #4/4 and #4/6 received 10
8 vge, animal #4/
51 0
5 vge). Viremia (Figure 5A) was already high at day 6 p.i. in all
animals inoculated with 10
8 vge; viral load in animal #4/5 was
initially low but increased to similar levels by week 7. Du-He4
viremia in animal #4/19 declined, yet the two others maintained
very high viral loads (around 10
10 vge/ml) over 15 weeks.
For vertical transmission two persistently Du-He4 infected
females were crossed with a DHBV negative drake. Six off-spring
embryos were sacrificed 5 to 9 days before hatch (d 28), and viral
DNA in the livers was analyzed for Du-He4 genotype (Figure S2B)
and quantitated by qPCR. All samples were positive for Du-He4
DNA (Figure 5B). Hence chimera Du-He4 could horizontally and
vertically be transmitted in ducks.
Chimeric envelope of Du-He4 mediates poor infectivity
for PDH but allows efficient spread in ducks
The disparate in vitro versus in vivo results for Du-He4
prompted us to thoroughly exclude that we had underestimated its
in vitro or overestimated its in vivo infectivity. Improper
modification of the chicken LMH cell-derived Du-He4 virions
did not account for poor PDH infectivity because Du-He4 virions
sequentially passaged through two ducks were similarly attenuated
(Figure 6A and 6B); this makes it also unlikely that the fast in vivo
spread of Du-He4 (see below) resulted from quickly arising
Figure 4. Selected D-PreS segments can enhance PDH infec-
tivity of HHBV pseudotypes. PDH were inoculated with env
2 DHBV
(left panel) and HHBV genomes (right panel) pseudotyped with the
indicated envelope proteins. Cells were harvested at day 7 p.i., and
intracellular viral DNAs were analyzed by Southern blotting. He-S
indicates that the L proteins consisted of an HHBV S domain combined
with the indicated PreS domains; no PreS, complementation with DHBV
S only. Levels of cccDNA were determined by phosphorimaging and are
given relative to autologously pseudotyped DHBV at MOI 1,000 (upper
lane), and to D-PreS/He-S pseudotyped HHBV.
doi:10.1371/journal.ppat.1000230.g004
Figure 5. In vivo transmission of Du-He4 virus in ducks. (A)
Horizontal transmission. Three ducklings each were inoculated with
serum from a duck previously infected with recombinant Du-He4 virus
(animals #4/17, #4/18, #4/19: 10
8 vge; black lines), or with recombi-
nant tagged wild-type DHBVm1 (animals #4/4, #4/6: 10
8 vge; animal
#4/5: 10
5 vge; grey lines). Viremia was monitored over 15 weeks by
qPCR. (B) Vertical transmission. Two persistently Du-He4 infected
females were crossed with a DHBV-negative drake. Six off-spring
embryos were sacrificed before hatch and their livers were analyzed for
viral DNA. Du-He4 DNA loads were quantitated by qPCR and are given
as vge/cell for each of the embryos.
doi:10.1371/journal.ppat.1000230.g005
Avihepadnavirus Host Range Determinants Revisited
PLoS Pathogens | www.plospathogens.org 5 December 2008 | Volume 4 | Issue 12 | e1000230adaptive mutations not detectable by restriction genotyping. A
significant replication defect of the Du-He4 genome in PDH that
went unnoticed in LMH cells was ruled out by pseudotyping the
env
2 DHBV genome, and an analogous env
2 Du-He4 genome,
with either wild-type D-PreS/S, or with Du-He4 PreS/S. The
chimeric envelope was up to ten-fold less efficient in rescueing
infectivity of both env
2 genomes whereas replication of the Du-
He4 genome was only slightly retarded at day 3 p.i. but reached
DHBV-like levels at day 7 p.i. in both settings (Figure 7).
In the previous in vivo experiments, Du-He4 had reached wt-
DHBV-like viral loads (Figure 4A) but slowed-down kinetics of
spread would not have been detected. We therefore monitored the
spread of both viruses, in liver and serum, at shortly spaced
intervals. Ten ducklings each received 10
8 vge of serum-derived
Du-He4 (from duck #4/17) or DHBVm1 (from duck #4/6). One
animal each was sacrificed at days 1, 2, 3 and 5 p.i., and two
animals each at days 7, 10 and 14 p.i.. Intrahepatic viral DNA was
analyzed by Southern blotting (Figure 8A), and the course of
viremia by DNA dot blot of serum samples (Figure S3); both data
sets were quantitated by phosphorimaging (Figure 8B). For
DHBVm1, intrahepatic virus DNA became clearly detectable at
day 5, then rapidly rose to maximal values at day 10, and slightly
declined. Du-He4 produced a very similar profile, except that
signals at the early timepoints (days 2 to 5; see Figure 8A) were
even stronger. Viremia was monitored in individual serum samples
from all animals alive at a given time-point (i.e. ten for day 1, two
for day 14). The mean and maximal values were again higher and
displayed a faster rise for the chimera than for the wild-type virus.
While the viremia values are statistically significant, especially for
the early time points covering samples form several ducks, each
liver data is derived from an individual duck and thus should not
be overinterpreted to indicate superiority of one virus over the
other. However, if the about 10-fold lower PDH infectivity of Du-
He4 had translated into a 10-fold lower percentage of initially
infected cells, i.e. about 1% instead of 10% [40], the appearance of
detectable levels of the chimeric virus should have occurred with a
substantial delay. For wild-type DHBV in young ducklings, the
mean doubling time in the percentage of infected hepatocytes has
been estimated to be about 16 h [40], thus three to four times this
time (2 to 3 d) would have been required for Du-He4 to catch up
with the wild-type virus, provided replication per se proceeded at
similar rates. As no such delay was observed, wild-type and
chimeric virus appear to spread with comparable kinetics.
In these experiments the viral loads showed less variation with
Du-He4 than with wild-type DHBV where such variability has
been seen also in other studies [44]. Because DHBV is wide-spread
in commercial flocks, including the animals in the current study,
mother-to-egg transmission of anti-DHBV antibodies, usually
directed against the envelope [29], could reduce or prevent viral
spread in some of the ducklings [30]. To test whether Du-He4
represented an a priori immune escape variant we preincubated
Du-He4, or DHBVm1 containing sera with a previously
Figure 6. Poor in vitro infectivity of Du-He4 is not an artifact of
the recombinant virions. PDH were inoculated with serum-derived
rather than recombinant virions (DHBVm1 from animal #4/6; Du-He4
from animal #4/17). (A) Kinetics of infection. PDH inoculated with DHBV
or Du-He4 at MOI 100 were harvested at the indicated time points. Viral
DNAs were analyzed by Southern blotting. The panels below show
Western blot signals for DHBV core protein (using mAb 2B9 4F8 [71])
and tubulin from the same lysates used to prepare viral DNA. (B) Du-
He4 envelope is at least ten-fold less efficient than the wild-type DHBV
envelope in mediating PDH infection. PDH were incubated with the two
viruses at the indicated MOIs. Cells were harvested 7 days p.i., and viral
DNAs were analyzed by Southern blotting. Note that signals for Du-He4
at MOI 100 were only slightly stronger than for DHBV at MOI 1
(connected arrows).
doi:10.1371/journal.ppat.1000230.g006
Figure 7. Poor in vitro infectivity of Du-He4 is largely caused by
the chimeric envelope. The env
2 DHBV genome and a correspond-
ingly mutated Du-He4 genome were trans-complemented by the
authentic D-PreS/S envelope or the chimeric Du-He4-PreS/S envelope,
and the resulting pseudotypes were used to inoculate PDH at MOI 100.
Cells were harvested at day 3 or day 7 p.i., and viral DNAs were analyzed
by Southern blotting and quantitation by phosphorimaging of the
cccDNA signals, assigned by a dilution series of a 3 kb DHBV sequence
containing plasmid DNA and by qPCR of intracellular RIs. The
corresponding values, normalized to those obtained with the D-PreS/
S complemented DHBV genome at day 7 p.i. set at 100%, are given
below each lane. Note that low signal intensities resulted largely from
the chimeric Du-He4 envelope, not the chimeric genome.
doi:10.1371/journal.ppat.1000230.g007
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DNA immunization with a DHBV16 PreS/S expression vector
and shown to react predominantly with PreS rather than S [28], or
for control with normal duck serum. Aliquots containing 10
6 vge
Du-He4 were inoculated into two ducklings each. In the test
animals (#7/1, #7/2), viral loads as determined by qPCR (Figure
S4) remained close to or at the detection limit of our non-nested
qPCR assay (about 100 vge per PCR reaction, corresponding to
10
5 vge/ml per 1 ml serum sample) between day 4 and day 11 p.i.;
by day 28, serum from one animal was essentially negative for viral
DNA, the other had developed a low titered viremia of
1.6610
5 vge/ml. In contrast, both control animals (#7/3, #7/
4) developed DHBs antigenemia, easily detectable by day 11 and
day 28 p.i., and viremia which peaked at 2.2 and 6.5610
8 vge/ml
on day 11. The antiserum also strongly reduced infectivity in one
(#7/6), and partially in the second (#7/5) DHBVm1 inoculated
duck, whereas the control animals (#7/7,8) developed antigen-
emia and viremia at a similar rate and to similar levels as the Du-
He4 controls (Figure S4). These data suggest that antibodies raised
against the wild-type DHBV surface proteins can also neutralize
the chimeric virus; in addition, they demonstrated that 10
6 vge of
Du-He4 could establish in vivo infection in ducks.
Estimating the specific infectivity of the Du-He4 chimera
One wild-type DHBV genome has been proposed to be
infectious in neonatal ducks [40]; for the human virus, the doses
required to infect 50% of the inoculated chimpanzees (CID50)
have been reported to range between 3 and 169 vge [45]. It was
therefore of interest to see whether replacement of the supposed
HDR in Du-He4, though principally compatible with in vivo
infectivity (see above), negatively affected specific infectivity. To
this end, 6 ducklings each were inoculated with DHBVm1 (from
duck #2/7) and Du-He4 (from duck #2/20) viremic sera, diluted
with normal duck serum to contain 10
7,1 0
5.5,1 0
4, and 10
2.5
(=300) vge per dose. Development of antigenemia and viremia
was monitored for up to 42 days p.i.; at the end of the experiment,
animals were sacrificed and the livers were removed for
determination of intrahepatic viral DNA.
Analysis of the serum samples revealed that at the highest dose,
6 of 6 animals from the DHBVm1 and 5 of 6 animals from the
Du-He4 group had developed antigenemia and viremia, easily
detectable by day 12 p.i. and persisting to end of the experiment;
for the 10
5.5 inocula, 5 of 6 animals in each group were positive for
serum markers of infection. Slight differences became apparent at
the lowest doses (Figure 9A); with the 10
4 vge inocula 3 of 6 Du-
He4 inoculated versus 5 of 6 DHBVm1 inoculated birds
developed antigenemia and viremia (titers in all cases around or
slightly above 10
9 vge/ml); with the 300 vge inocula, numbers
were none out of 6 versus 2 out of 6. Formal ID50 values as
calculated from the fraction of animals positive for serum PreS
antigen at the end of the experiment by the Spearman-Ka ¨rber
method [46] were 10
3.3 (about 2,000; 95% confidence interval
10
2.2–10
3.8) vge for the wild-type virus and 10
4.5 (about 30,000;
95% confidence interval 10
3,6–10
5,4) vge for Du-He4; the Reed-
Mu ¨nch method [47] yielded ID50 values of 10
3 for wild-type
DHBV and 10
4 vge for Du-He4. Though only a trend given the
limited number of animals, this was compatible with a somewhat
reduced efficiency of Du-He4 in establishing an overt in vivo
infection at low inoculum doses.
However, in their livers all animals inoculated with 300 vge of
Du-He4, as well the wild-type DHBV inoculated ducks that had
remained negative for serum markers of infection, contained very
low but Southern blot detectable amounts of viral DNA (Figure 9A,
bottom panel). As determined by qPCR, the livers of the serum
Figure 8. Quantitative comparison of in vivo spread of Du-He4
versus wild-type DHBV. Ten ducklings each were inoculated with
serum containing 10
8 vge of Du-He4 (from animal #4/17) or DHBVm1
(from animal #4/6). One animal each was sacrificed at days 1, 2, 3, and 5
p.i. and two animals each at days 7, 10, and 14 p.i.; intrahepatic virus
DNA and viremia were quantitatively monitored by Southern blot and
DNA dot blot, respectively. Animal #9/9 from the DHBVm1 group
showed no signs of productive infection and was excluded from further
analysis. (A) Intrahepatic DNA. DNA from liver autopsies was analyzed
by Southern blotting. (B) Quantitation of intrahepatic and circulating
virus DNA. Signal intensities from appropriate exposures of the
Southern blots shown in A were quantitated by phosphorimaging
and normalized to an identical amount of DHBV marker DNA present on
both gels. Error bars indicate the deviation between two independent
DNA preparations from one animal (samples from days 1, 2, 3, 5, and
day 10 for DHBVm1) or from two independent DNA preparations from
two animals (all others). To monitor viremia, serum samples were
collected at all indicated time points until the respective animal was
sacrificed. Titers were determined by DNA dot blot (Figure S3) and
phosphorimaging. The thick lines represent the mean values of all
samples from one group, the dashed lines the minimal and maximal
values from individual samples.
doi:10.1371/journal.ppat.1000230.g008
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200 vge/cell, as did the liver of animal #21/21 from the wild-type
virus group that was negative for serum antigen but had a low level
viremia (7610
6 vge/ml versus about 1.5610
9 vge/ml for the
antigenemic ducks). Livers from all other animals contained
between 0.01 and 0.20 vge/cell. Though the accuracy of these
numbers is limited, even the lowest values were at least five times
above background. Most importantly, extrapolated to the entire
liver (liver weights 30–50 g at the time the animals were sacrificed)
and assuming 7610
8 cells per gram liver [48,49], even 1 vge per
100 cells translates into a total of 2610
8 vge per animal, indicating
a 6 log amplification of the input virus. Because according to these
data all 6 ducklings receiving 300 vge of Du-He4 were initially
infected, as were the four non-antigenemic wild-type DHBV
inoculated ducks, a formal ID50 cannot be calculated; however, it
must be well below 300 vge. Thus although a low dose infection
with Du-He4 may be more effectively contained by the host than
infection with wild-type DHBV, heterologous replacement of the
PreS region supposedly critical for the duck tropism of DHBV had
no major negative impact on specific infectivity in ducks.
Discussion
The essential role of the preS domains for hepadnavirus infection
is indisputable.Hence the model that a specificsegment withinPreS
determines host range is plausible, and it is experimentally
supported by pseudotype - PDH infection data [23]. Our results
confirm significant aspects of these previous findings, including the
ability of D-PreS 22–37 to enhance PDH infectivity of heterologous
pseudotypes and thus to affect host specific infectivity in that test
system; however, they also preclude the generalized conclusion that
this sequence, or its longer counterpart 22–90, constitutes the
avihepdnaviral host-determining region. In the context of the
DHBV envelope, replacement of D-PreS 22–37 by HHBV
sequence (Du-He2) had no negative impact on infectivity at all
and, most importantly, a duck virus chimera in which the entire
region suggested to determine duck tropism was replaced by heron
virus sequence (Du-He4) was highly infectious for ducks. Hence the
factors that determine infectivity in vitro are not the same as in vivo.
Our study therefore unveils fundamental gaps in the current
understanding of hepadnaviral host tropism.
Individual PreS segments affect infectivity for isolated
hepatocytes in a non-reciprocal and non-linear fashion
An absolute requirement for the infection experiments was that
the chimeras be able to produce intact enveloped virions. None of
the chimeras reported here displayed any obvious defects, as most
compellingly demonstrated by their in vivo infectivity.
Nonetheless, chimeras Du-He3 and Du-He4, but not Du-He2,
were poorly infectious for PDH; these in vitro data, performed on
the same batch of PDH for the different viruses and reproduced
several times, are statistically highly significant (P,0.001,
Student’s t-test). Hence replacement of D-PreS 22–90, 38–90,
and also 91–160 (Du-He7; not shown), by He-PreS segments
substantially reduced infectivity for PDH but replacement of D-
PreS 22–37 did not. Simply interpreted, DHBV specific sequences
downstream of aa 37 were required for efficient infection of duck
hepatocytes but the sequence 22–37 was not. Thus in this test
system, D-PreS 22–37 had no species-specific impact although the
same sequence significantly enhanced PDH infectivity of the
HHBV pseudotypes; in other words, reciprocal exchanges of PreS
segment 22–37 did not produce reciprocal phenotypes.
Other data sets also elude a simple interpretation. D-PreS 22–37
and 22–108 enhanced PDH infectivity of HHBV pseudotypes as
reported [23], yet 22–90, and 1–90, did not; pseudotype formation
with these latter constructs was as efficient as with the others, and
numerous of the pseudotypes prepared and tested in parallel
(Figure 4) clearlyscoredpositive.Thusthere is no linearrelationship
Figure 9. Estimating the specific in vivo infectivity of Du-He4 versus wild-type DHBV. (A) PreS antigenemia after inoculation with 10
4 vge
of DHBVm1 or Du-He4. PreS antigenemia was monitored by Western blotting with mAb 4F8, using 0.5 ml of the final sera from the indicated animals
per lane; birds #21/14, 16, and 18 were scored positive because the signals, though weak, were above background. (B) Antigenemia and intrahepatic
viral DNA after inoculation with 300 vge of DHBVm1 or Du-He4. PreS/S antigenemia was monitored as in A. Intrahepatic DNA was analyzed by
Southern blotting, using 5 mg of total liver DNA per sample. The long exposure (bottom panel; exposed 6 times longer and using an intensifying
screen) revealed weak signals at the expected position for all ducks inoculated with 300 vge of Du-He4 (arrow); a corresponding signal for duck #21/
24 from the wild-type group is covered by the strong signal from the neighboring #21/23 sample. The presence of viral DNA in all samples was
confirmed by qPCR. (C) Summary of fraction of birds positive for individual infection markers. Numbers from the column PreS Ag were used to
calculate formal ID50 values.
doi:10.1371/journal.ppat.1000230.g009
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hepatocytes from the homologous host. This suggests that
consecutive PreS segments act as multimodular three-dimensional,
not linear, structures that may undergocomplex and dynamic intra-
and intermolecular interactions. Given the limited [50] or absent
knowledgeonthe structure ofPreS and itsrelevantcellularpartners,
attempts to define a linear sequence segment as critical for host
range determination therefore appear to be doomed.
This conclusion is supported by in vitro infectivity data obtained
with hepatitis delta virus particles carrying chimeric hepadnavirus
envelopes [51]. Replacement of the N terminal HBV PreS1 segment
1–40 by that from WMHBV reduced, indeed, HDV infectivity for
human hepatocytes, in accord with a previous HBV pseudotype
study [36]; however, infectivity for spider monkey cells was likewise
reduced, although in vivo WMHBV can infect the woolly monkey
related spider monkeys but not chimps [52]. Even more surprisingly,
reciprocal introduction of human virus PreS1 1–40 into a WMHBV
envelope did not enhance infectivity for human cells yet even strongly
boosted infectivity for spider monkey hepatocytes [37]. These data
cannot be reconciled with the simple concept of a defined sequence
segment in PreS acting as a host range determinant.
The most compelling counterevidence, however, comes from the
in vivo infection experiments in this study. In ducks, Du-He4
established high-titered persistent infections; the kinetics of intrahe-
patic spread after inoculation with 10
8 vge/duckling were compara-
ble and, in no case, slower than with wild-type DHBV (Figure 8). At
inoculum doses of 10,000 or 300 vge/animal, wild-type DHBV
seemed to be somewhat more efficient regarding the fractions of birds
developping antigenemia and viremia (Figure 9), with formal ID50
values of around 10
4 for Du-He4 vs. 10
3 for wild-type DHBV;
however, the smallnumber of animalsimposes the same limitation on
such an interpretation as the seemingly better performance of the
c h i m e r aa tt h e1 0
8 vge inocula. Most importantly, all animals
inoculated with only 300 vge and negative for serum markers of
infection contained intrahepatic viral DNA. Because the absolute
copy numbers determined by qPCR were low (350 to 2,000 copies
per PCR reaction) the estimates of between 0.2 and 0.01 vge per cell
may not be very accurate. Clearly, however, even one vge per 100
cells amounts to a total of more than 10
8 vge per duck liver [49],
demonstrating a 10
6-fold, or higher, amplification of the inoculum.
Thus 300 vge of Du-He4, as well as of wild-type DHBV, were
sufficient for an at least initial infection of 6 out of 6 ducklings. This
prevented calculation of a formal ID50 value; as an approximation to
the upper limit of the actual ID50 it may be assumed that the next
lower dilution would have infected only a fraction of animals; in our
experiments, this would correspond to an input of 10 vge per animal,
c l o s et ot h ev a l u er e p o r t e df o rw i l d - t y p eD H B V[ 4 0 ] .
Whether or not the chimeric genomes accumulated mutations,
and if so which, upon multiple passages in the duck is currently
being investigated using serial samples, yet maintainance of the
low PDH infectivity phenotype after passage in ducks (Figure 6) as
well as preliminary sequencing data make it unlikely that rapidly
occurring adaptive mutations [53] caused the high in vivo
infectivity. Thus, Du-He4 is a fully functional duck-infectious
avihepadnavirus although nearly half its PreS sequence is from a
virus that does not infect ducks and although the heterologous
sequence clearly reduced infectivity for duck hepatocytes. Thus the
predictive significance of in vitro infectivity data for in vivo
infectivity is strongly limited.
Implications of distinct in vitro versus in vivo infectivity of
chimera Du-He4
The high in vivo versus low in vitro infectivity of Du-He4 points
to major differences between the two settings even though the
primary hepatocytes originated from the same species as the
experimental animals. In fact, even for wt-DHBV the amounts of
virus required for PDH infection appear high given that few DHB
virions can establish infection in ducks ([40] and this study), and
this difference seems to be further magnified in the Du-He3 and
Du-He4 chimeras. Possibly, the expression profiles of cell factors
required for, or restricting infection [5], such as those controlling
retroviruses [54,55], differ between hepatocytes in culture versus in
the liver, and the chimeras are more sensitive to such alterations.
Alternatively, the intact liver may have a higher capacity for as yet
undefined processing steps in the envelope that increase infectivity,
or its tissue architecture provides for particularly intimate contacts
between hepatocytes and incoming virus that outbalance a
reduced affinity of the chimeric preS regions for the unknown
receptors; it has even been proposed that liver sinusoidal
endothelial cells, not hepatocytes, are the initial in vivo target
cells [56], yet the physiological relevance of this model is unclear.
For several viruses, spread is particularly efficient via direct cell-to
cell contacts, such as filopodial bridges [57] or the recently
described nanotubes [58]; such processes may also contribute to
the efficiency of hepadnaviral spread in vivo yet not, or less so, in
cultured hepatocytes.
Another conceivable option for the high in vivo infectivity of Du-
He4 was that the chimera had a selective advantage relating to
preexisting (possibly present in some of our animals), or rapidly
inducible antibodies that neutralize the wild-type virus [31] but not
the chimera. Our neutralization experiments argue against but do
not fully exclude this possibility. The antiserum used reacted on
Western blots virtually exclusively with the L protein but not the S
protein of DHBV, as reported [28], and the chimeric Du-He4 L
protein was recognized with similar efficiency. Though in accord
with its neutralizing activity against Du-He4, it is not clear whether
the fraction of Western blot reactive antibodies in the antiserum, or
possibly others directed against the native L and/or S protein, are
the relevant ones for neutralization, and the fraction of these
relevant antibodies might differ for wild-type DHBV and Du-He4.
Notably, Du-He3 and Du-He4 infectivity for PDH was not as
strongly reduced (by around 10-fold) as that of HHBV (.100-fold),
which might suggest that there is a threshold in vitro infectivity that
is compatible with in vivo infection. Along this line, approximate
quantitation of the PDH infectivities of recombinant Ross’ Goose
(RGHBV; Genbank accession: AY494848), snow goose (SGHBV;
Genbank accession: AF110997), and stork hepatitis B (STHBV;
Genbank accession: AJ251937) viruses showed reductions of 8 to
20-fold for the goose viruses and .100-fold for STHBV (K.
Dallmeier and M. Nassal, unpublished data). While, to our
knowledge, no in vivo infection data have been published for these
viruses, a virus almost identical to RGHBV isolated from Mandarin
ducks was indeed infectious for ducks [59], and STHBV would be
predictednottoinfectducks.Thusanabout 10-foldreductioninthe
efficiency of virus uptake, which is probably what is reflected by the
data obtained on isolated hepatocytes, may not be rate-limiting for
virus spread in vivo.
However, not any virus displaying an intermediate (as opposed
to a drastic) reduction in in vitro infectivity is able to establish in
vivo infection. Of 6 ducklings inoculated with 10
8 vge of chimera
Du-He7 none developed signs of infection although the chimera
produced similar amounts of enveloped particles in transfected
LMH cells and had a similar in vitro infectivity as Du-He3 and
Du-He4. The same was observed with a DHBV chimera in which
the core gene was replaced by that from HHBV (Dallmeier and
Nassal, unpublished). Similarly, a natural avihepadnavirus isolate
from an Ashy-headed sheldgoose (ASHBV; Genbank accession:
NC_005890) with reduced but clearly detectable infectivity for
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to be no simple correlation between in vitro and in vivo infectivity.
Given these various uncertainties, testing in vivo infectivity
appears currently as the only reliable way of addressing
hepadnaviral host range.
This conclusion may be relevant for the risk assessment of
vaccine escape and drug resistant variants of human HBV. De
novo infection with such mutants could seriously impair efficacy of
vaccination and restrict the options for chronic hepatitis B
treatment [60]. Some resistance-conferring mutations seem to
lower replication capacity [61], yet their effect on infectivity is not
known. Notably, for HBV the discrepancy between highly efficient
in vivo infection [45] and the requirement for MOIs of 10 or
higher, and often for polyethylenglykol as an additional facilitator
[51,62,63], in the current cell culture infection systems is even
more pronounced than for DHBV. Hence cell culture data may
not be dependably extrapolated to the behaviour of such viruses in
vivo. Even if our in vivo titration data were interpreted as evidence
for a somewhat reduced specific infectivity of Du-He4, this was
manifest only at inoculum doses of 10
4 vge or less; given that HBV
titers in humans frequently exceed 10
9 vge per ml, such a dose
would be contained within 10 nl of blood, only a fraction of what
is commonly transferred in needlestick injuries with even the finest
(25G) needles [64]. Hence fundamental questions in hepadnavirus
infection biology will need to be reassessed, not only regarding the
identity of the still obscure cellular factors involved but also with
respect to the seemingly well understood role of the viral envelope
proteins in mediating infectivity and tissue and host tropism.
Materials and Methods
Full protocols and details of plasmid constructions are supplied
as Protocol S1 in Supporting Information.
Expression constructs for recombinant viruses and
envelope proteins
Virus expression vectors were based on plasmid pCD16,
carrying a CMV promoter controlled 1.16 DHBV16 genome
[65]; the tagged derivative DHBVm1 contained three nt
substitutions that created new restriction sites for BsmBI and
MroI (Figure S1). Chimeric DHBV genomes encoded the
following aa replacements: Du-He2, D-PreS 22–37 by He-PreS
22–40; Du-He3, D-PreS 38–90 by He-PreS 38–92; Du-He4: D-
PreS 22–90 by He-PreS 22–92 (Figure 1C). Vector pCHHBV4
was based on HHBV4 (Genbank accession: NC_001486) [24].
Envelope-deficient (env
2) DHBV and HHBV genomes corre-
sponded to those described earlier [23,33,66]. PreS/S expression
vectors were all controlled by the CMV promoter; the CHBV
PreS construct contained a segment from CHBV1 [22], kindly
provided by H. Sirma and H. Will.
Replication competence and enveloped virion formation
Intracellular replicative intermediates (RIs) from transfected
LMH cells were analyzed by Southern blotting of DNAs from
cytoplasmic extracts; secreted virions were enriched by D-PreS-
specific immunoprecipitation, then subjected to endogenous
polymerase assay conditions [67,68] with or without detergent.
Alternatively, viral DNA in enveloped particles was enriched by
pronase plus nuclease treatment [33] and used for quantitative
PCR (qPCR) determinations. Recombinant viruses were obtained
analogously; pseudotypes were generated by cotransfection of
vectors encoding an env
2 viral genome and the desired PreS/S
proteins. Viral titers, as viral genome equivalents per ml (vge/ml),
were determined by DNA dot blot or by qPCR.
In vitro infections
Primary duck hepatocytes [69] were usually incubated over-
night at the desired MOI with recombinant virus, or with viremic
duck serum. For analysis of intracellular viral DNAs including
cccDNA, total DNA was prepared by SDS lysis [66].
In vivo infections
Two to three day old Pekin ducklings were injected into the foot
vein with the indicated amounts of recombinant virus or viremic
serum. Viremia was determined as described above for cell culture
supernatants. To monitor the kinetics of viral spread in the liver,
one or two animals each were sacrificed at each time-point, and
liver DNA was analyzed by virus specific Southern blot. To
estimate specific infectivities, six ducklings each were inoculated
with viremic sera diluted to contain 10
7,1 0
5.5,1 0
4, and 10
2.5 vge
per dose of either the reference virus DHBVm1 or Du-He4.
Serum samples were collected for up to 42 days, and PreS
antigemia was monitored by Western blotting; viral loads in
selected PreS antigen positive animals were determined by qPCR.
At the end of the experiment, the animals were killed and their
livers were removed to monitor intrahepatic viral DNA by
Southern blotting and by qPCR. The fractions of animals positive
for serum PreS antigen were used to calculate formal ID50 values
using the Spearman-Ka ¨rber [46] and the Reed-Muench method
[47]. All animal experiments were approved by the local
authorities (Regierungspra ¨sidium Freiburg, project G02/36) and
performed in compliance with German animal welfare legislation
at a registered facility of the University Hospital Freiburg under
veterinary supervision.
Supporting Information
Protocol S1 Supporting Materials and Methods. This file
contains a detailed description of experimental procedures not
contained in the brief general M+M section of the main text, plus
a list of supporting references.
Found at: doi:10.1371/journal.ppat.1000230.s001 (0.14 MB
DOC)
Figure S1 Genetic tags for discrimination of chimeric from wild-
type viruses. A. Partial restriction maps of preS-derived PCR
amplicons from the viruses used in this study. DHBV16 and
DHBV3 are the predominant wild-type DHBV strains endemic in
the US and Europe, respectively. The tagged DHBV16 derivative
DHBVm1, used as reference wild-type virus, contains the
artificially introduced Bsm BI site present in all chimeras, and
the Mro I site present in Du-He3 and Du-He4. B. Genotyping of
selected chimeras after in vitro infection of PDH. The example
shows the restriction patterns of PCR amplicons obtained from
intracellular nucleocapsid-associated DNA of PDH inoculated
with the indicated recombinant viruses. Each amplicon produced
the expected unique pattern. The same type of analysis was used to
confirm infection by the desired virus variants in vivo and to
exclude congenital infection by DHBV3 or contamination with the
laboratory strain DHBV16.
Found at: doi:10.1371/journal.ppat.1000230.s002 (0.64 MB PDF)
Figure S2 Genetic tags are preserved upon in vivo infection of
ducks with chimeras Du-He2, Du-He3 and Du-He4. A. Serum
samples (day 7 p.i.) from ducks inoculated with the indicated
recombinant viruses. PCR amplicons were incubated with the
indicated restriction enzymes and the products were analyzed by
agarose gel electrophoresis. B. Serum sample from vertical
transmission experiment (embryo #e1). All samples produced
input-virus specific fragment patterns (see Figure S1).
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Figure S3 In vivo spread of Du-He4 is as fast as, or faster than
that of wild-type DHBV. Ten ducklings each were inoculated with
serum-derived DHBVm1 (from animal #4/6) or Du-He4 (from
animal #4/17) and analyzed as described in the legend to
Figure 8. Animal #9/9 from the DHBVm1 group showed no
signs of productive infection and was excluded from further
analyis. A. Kinetics of viremia. Serum samples from the indicated
animals were collected at the indicated days p.i. and analyzed by
DNA dot blot using a 32P labeled bispecific DNA probe; one out
of several exposures is shown. The day 2 sample from animal #9/
18 could not be analyzed. B. DNA dot blot of DHBV plasmid
DNA standard used for calibration. A dilution series of plasmid
pCD16 DNA containing the indicated amounts of viral genome
equivalents was dotted on a membrane and detected with the
identical probe as the dot blots shown in A. A graphic
representation of the resulting values is shown in Figure 8B.
Found at: doi:10.1371/journal.ppat.1000230.s004 (0.41 MB PDF)
Figure S4 Du-He4 is neutralized by duck sera against wild-type
DHBV L protein. Serum samples containing 107 vge/ml of Du-
He4 (from animal #4/17) or DHBVm1 (from animal #4/6) were
incubated with an equal volume of a previously characterized
DHBV neutralizing duck antiserum (a-DPreS/S), or with normal
duck serum (NDS), for 1 h at room temperature. Aliquots
containing 106 vge were inoculated into two ducklings each
(animals #7/1,2: Du-He4+a-DPreS/S; #7/3,4: Du-He4+NDS;
#7/5,6: DHBVm1+a-DPreS/S; #7/7,8: DHBVm1+NDS). Vi-
remia was monitored by qPCR for 28 d p.i.; values below
104 vge/ml are close to the detection limit and may not be very
accurate. In animal #7/5 (DHBVm1+a-DPreS/S; not shown)
development of viremia was delayed but an increase in viral load
from 8.36103 vge/ml at d 7 p.i. to 6.16106 vge/ml at d 11
indicated partial protection.
Found at: doi:10.1371/journal.ppat.1000230.s005 (0.06 MB PDF)
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